LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Stock List・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Closed

SectorHealthcare

21.32 -0.84

Buy Sell

Overview

Share price change

24h

Current

Min

21.2

Max

21.7

Key metrics
By Trading Economics
Income	-29M -11M
Sales	-24M 105M
EPS	-0.09
Profit margin	-10.717
Employees	354
EBITDA	-31M -8.5M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+62.43% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-281M 2.7B
Previous open	22.16
Previous close	21.32

News Sentiment

By Acuity

50%

137 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

12.42 / 14.93 Support & Resistance

Arcutis Biotherapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

15 May 2026, 22:47 UTC

Hot Stocks

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 May 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 May 2026, 22:00 UTC

Major Market Movers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 May 2026, 18:09 UTC

Major Market Movers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 May 2026, 16:02 UTC

Earnings

Major Market Movers

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 May 2026, 14:55 UTC

Major Market Movers

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

16 May 2026, 16:27 UTC

Acquisitions, Mergers, Takeovers

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 May 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 May 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 May 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 May 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 May 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 May 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 May 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 May 2026, 20:19 UTC

Hot Stocks

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 May 2026, 19:41 UTC

Acquisitions, Mergers, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 May 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 May 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 May 2026, 18:35 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 May 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 May 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 May 2026, 16:24 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 May 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 May 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 May 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 May 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 May 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 May 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 May 2026, 15:20 UTC

Earnings

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

Peer Comparison

Price change

Arcutis Biotherapeutics Inc Forecast

Price Target

By TipRanks

62.43% upside

12 Months Forecast

Average 34.63 USD 62.43%

High 36 USD

Low 33 USD

Based on 8 Wall Street analysts offering 12 month price targets forArcutis Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Arcutis Biotherapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

12.42 / 14.93Support & Resistance

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

137 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.